About Fulgent Genetics (NASDAQ:FLGT)
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLGT
CUSIPN/A
Phone626-350-0537
Debt
Debt-to-Equity RatioN/A
Current Ratio10.97%
Quick Ratio10.97%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$18.73 million
Price / Sales3.82
Cash Flow$0.0035 per share
Price / Cash1,131.61
Book Value$3.04 per share
Price / Book1.32
Profitability
EPS (Most Recent Fiscal Year)($0.11)
Net Income$-2,510,000.00
Net Margins-14.21%
Return on Equity-4.05%
Return on Assets-3.83%
Miscellaneous
Employees98
Outstanding Shares17,880,000
Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions
What is Fulgent Genetics' stock symbol?
Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."
How were Fulgent Genetics' earnings last quarter?
Fulgent Genetics (NASDAQ:FLGT) released its earnings results on Wednesday, February, 28th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.06. The firm had revenue of $4.28 million for the quarter, compared to the consensus estimate of $5.26 million. Fulgent Genetics had a negative return on equity of 4.05% and a negative net margin of 14.21%. View Fulgent Genetics' Earnings History.
When is Fulgent Genetics' next earnings date?
What price target have analysts set for FLGT?
2 analysts have issued 1 year target prices for Fulgent Genetics' shares. Their forecasts range from $6.00 to $7.00. On average, they anticipate Fulgent Genetics' share price to reach $6.50 in the next year. View Analyst Ratings for Fulgent Genetics.
Who are some of Fulgent Genetics' key competitors?
Who are Fulgent Genetics' key executives?
Fulgent Genetics' management team includes the folowing people:
- Mr. Ming Hsieh, Chairman, Chief Exec. Officer, Pres and Mang. of Fulgent LLC (Age 62)
- Mr. Paul Kim, Chief Financial Officer (Age 51)
- Dr. Han Lin Gao M.D., Ph.D., D.A.B.M.G., F.A.C.M.G., Chief Scientific Officer and Lab Director (Age 51)
- Joe Roach, VP
When did Fulgent Genetics IPO?
(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.
Has Fulgent Genetics been receiving favorable news coverage?
Headlines about FLGT stock have been trending positive recently, Accern reports. The research group rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fulgent Genetics earned a news sentiment score of 0.46 on Accern's scale. They also gave media coverage about the company an impact score of 45.01 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Fulgent Genetics?
Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fulgent Genetics' stock price today?
One share of FLGT stock can currently be purchased for approximately $4.00.
How big of a company is Fulgent Genetics?
Fulgent Genetics has a market capitalization of $71.51 million and generates $18.73 million in revenue each year. The company earns $-2,510,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Fulgent Genetics employs 98 workers across the globe.
How can I contact Fulgent Genetics?
Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]
MarketBeat Community Rating for Fulgent Genetics (FLGT)
MarketBeat's community ratings are surveys of what our community members think about Fulgent Genetics and other stocks. Vote "Outperform" if you believe FLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Fulgent Genetics (NASDAQ:FLGT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Fulgent Genetics in the last 12 months. Their average twelve-month price target is $6.50, suggesting that the stock has a possible upside of 62.50%. The high price target for FLGT is $7.00 and the low price target for FLGT is $6.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.50 | $6.50 | $7.25 | $8.50 |
| Price Target Upside: | 62.50% upside | 35.70% upside | 79.01% upside | 126.67% upside |
Fulgent Genetics (NASDAQ:FLGT) Consensus Price Target History
Fulgent Genetics (NASDAQ:FLGT) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Fulgent Genetics (NASDAQ:FLGT) Earnings History and Estimates Chart
Fulgent Genetics (NASDAQ FLGT) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/14/2018 | | | | | | | | |
| 2/28/2018 | Q4 2017 | ($0.03) | ($0.09) | $5.26 million | $4.28 million | View | N/A |  |
| 11/6/2017 | Q3 2017 | | ($0.05) | $5.52 million | $4.50 million | View | N/A | |
| 8/7/2017 | Q2 2017 | $0.0160 | $0.02 | $5.03 million | $4.64 million | View | Listen | |
| 5/8/2017 | Q1 2017 | $0.03 | $0.02 | $5.85 million | $5.31 million | View | Listen | |
| 2/27/2017 | Q416 | $0.04 | $0.05 | $5.99 million | $5.85 million | View | Listen | |
| 11/14/2016 | Q3 2016 | $0.08 | ($0.44) | $5.16 million | $5.01 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Fulgent Genetics (NASDAQ:FLGT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Fulgent Genetics (NASDAQ FLGT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 58.80%
Institutional Ownership Percentage: 7.92%
Fulgent Genetics (NASDAQ FLGT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/8/2018 | Paul Kim | CFO | Sell | 1,628 | $3.76 | $6,121.28 | 385,401 | |
| 11/30/2017 | Ming Hsieh | Insider | Buy | 2,000 | $3.60 | $7,200.00 | 6,549,707 | |
| 11/20/2017 | Ming Hsieh | CEO | Buy | 7,259 | $3.28 | $23,809.52 | 6,540,849 | |
| 11/16/2017 | Ming Hsieh | Insider | Buy | 2,205 | $3.23 | $7,122.15 | 6,540,849 | |
| 11/14/2017 | Ming Hsieh | Insider | Buy | 10,504 | $3.30 | $34,663.20 | | |
| 11/13/2017 | Paul Kim | CFO | Sell | 1,573 | $3.22 | $5,065.06 | | |
| 11/9/2017 | Ming Hsieh | CEO | Buy | 11,520 | $3.47 | $39,974.40 | 6,506,464 | |
| 8/11/2017 | Paul Kim | CFO | Sell | 6,134 | $5.71 | $35,025.14 | 388,602 | |
| 6/15/2017 | Ming Hsieh | Insider | Buy | 20,000 | $5.26 | $105,200.00 | 6,482,244 | |
| 6/13/2017 | Ming Hsieh | Insider | Buy | 30,000 | $4.98 | $149,400.00 | 6,459,944 | |
| 9/30/2016 | Ming Hsieh | Insider | Buy | 1,000,000 | $9.00 | $9,000,000.00 | | |
(Data available from 1/1/2013 forward)
Fulgent Genetics (NASDAQ FLGT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | OpGen (OPGN) and Fulgent Genetics (FLGT) Financial Comparison
www.americanbankingnews.com - April 25 at 1:26 PM |
 | Fulgent Genetics to Announce First Quarter 2018 Financial Results on Monday May 7, 2018
finance.yahoo.com - April 23 at 10:09 AM |
| Fulgent Genetics (FLGT) vs. Quest Diagnostics (DGX) Critical Survey
www.americanbankingnews.com - April 20 at 3:28 AM |
| Zacks: Analysts Set $4.35 Price Target for Fulgent Genetics (FLGT)
www.americanbankingnews.com - April 17 at 1:32 AM |
| Fulgent Genetics (FLGT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 10 at 5:02 PM |
| Fulgent Genetics (FLGT) Lifted to Hold at ValuEngine
www.americanbankingnews.com - April 8 at 12:30 PM |
| Analysts Set $4.35 Target Price for Fulgent Genetics (FLGT)
www.americanbankingnews.com - April 2 at 9:16 PM |
| Fulgent Genetics (FLGT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 30 at 9:04 AM |
| Fulgent Genetics (FLGT) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 29 at 8:30 PM |
| Fulgent Genetics (FLGT) Cut to "Neutral" at Piper Jaffray Companies
www.americanbankingnews.com - March 24 at 2:13 PM |
| Edited Transcript of FLGT earnings conference call or presentation 28-Feb-18 9:30pm GMT
finance.yahoo.com - March 18 at 10:32 AM |
| Analysts Set $4.35 Target Price for Fulgent Genetics Inc (FLGT)
www.americanbankingnews.com - March 14 at 7:21 PM |
| Fulgent Genetics (FLGT) PT Lowered to $6.00 at Credit Suisse Group
www.americanbankingnews.com - March 1 at 2:02 PM |
| Fulgent Genetics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 10:15 AM |
| Fulgent Genetics (FLGT) Posts Quarterly Earnings Results
www.americanbankingnews.com - February 28 at 7:36 PM |
| Brokerages Expect Fulgent Genetics Inc (FLGT) to Announce ($0.02) EPS
www.americanbankingnews.com - February 27 at 1:24 PM |
| Derma Sciences (DSCI) versus Fulgent Genetics (FLGT) Critical Review
www.americanbankingnews.com - February 24 at 11:18 PM |
| Zacks: Fulgent Genetics Inc (FLGT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 24 at 3:38 PM |
| Representatives of Fulgent Genetics to Participate in 2018 BTIG Healthcare Conference
finance.yahoo.com - February 23 at 10:37 AM |
| Zacks: Fulgent Genetics Inc (FLGT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 9:24 PM |
| Fulgent Genetics (FLGT) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 21 at 4:46 AM |
| Fulgent Genetics Inc (FLGT) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 18 at 5:10 AM |
| Fulgent Genetics to Announce Fourth Quarter and Full Year 2017 Financial Results on February 28, 2018
finance.yahoo.com - February 13 at 3:19 PM |
| Zacks: Fulgent Genetics Inc (FLGT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 9 at 9:10 PM |
| Analysts Anticipate Fulgent Genetics Inc (FLGT) to Announce ($0.02) Earnings Per Share
www.americanbankingnews.com - February 6 at 11:00 AM |
| Brokerages Set $7.00 Target Price for Fulgent Genetics Inc (FLGT)
www.americanbankingnews.com - January 21 at 5:46 AM |
| Zacks: Fulgent Genetics Inc (FLGT) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 5 at 5:32 PM |
| Fulgent Genetics Inc (FLGT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 2 at 9:10 PM |
| Comparing Nanosphere (NSPH) & Fulgent Genetics (FLGT)
www.americanbankingnews.com - December 26 at 8:01 PM |
| ETFs with exposure to Fulgent Genetics, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 1:50 PM |
| Fulgent Genetics, Inc. :FLGT-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017
finance.yahoo.com - December 23 at 6:11 AM |
| Zacks: Fulgent Genetics Inc (FLGT) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 16 at 1:52 AM |
| Brokerages Set $7.00 Price Target for Fulgent Genetic (FLGT)
www.americanbankingnews.com - December 1 at 3:48 PM |
| Analyzing Fulgent Genetic (FLGT) & InVivo Therapeutics (NVIV)
www.americanbankingnews.com - November 26 at 9:24 AM |
| Reviewing ViewRay (VRAY) and Fulgent Genetic (FLGT)
www.americanbankingnews.com - November 24 at 5:12 PM |
| Ming Hsieh Purchases 7,259 Shares of Fulgent Genetic (FLGT) Stock
www.americanbankingnews.com - November 21 at 4:40 PM |
| Fulgent Genetic (FLGT) Given $7.00 Average Target Price by Analysts
www.americanbankingnews.com - November 16 at 3:52 PM |
| Fulgent Genetic (FLGT) Insider Acquires $34,663.20 in Stock
www.americanbankingnews.com - November 15 at 9:32 PM |
| Fulgent Genetic (FLGT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 13 at 7:08 PM |
| Fulgent Genetic (FLGT) CEO Buys $39,974.40 in Stock
www.americanbankingnews.com - November 13 at 6:54 PM |
| Analyzing Digirad Corporation (DRAD) and Fulgent Genetic (FLGT)
www.americanbankingnews.com - November 10 at 5:48 PM |
| Edited Transcript of FLGT earnings conference call or presentation 6-Nov-17 10:00pm GMT
finance.yahoo.com - November 8 at 6:56 AM |
| Fulgent Genetic (FLGT) Price Target Cut to $7.50 by Analysts at Credit Suisse Group
www.americanbankingnews.com - November 7 at 10:28 PM |
| Fulgent Genetic (FLGT) Downgraded by Raymond James Financial, Inc.
www.americanbankingnews.com - November 7 at 11:33 AM |
| Fulgent Genetic (FLGT) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 6 at 10:50 PM |
 | Fulgent Genetics's (FLGT) CEO Ming Hsieh on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 6 at 10:38 PM |
| Fulgent Genetics, Inc. to Host Earnings Call
finance.yahoo.com - November 6 at 10:38 PM |
| Fulgent Genetics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 6 at 10:38 PM |
| Fulgent Genetic (FLGT) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 1:00 PM |
| Financial Comparison: GenMark Diagnostics (GNMK) & FULGENT GENETIC (FLGT)
www.americanbankingnews.com - October 30 at 5:16 AM |
Fulgent Genetics (NASDAQ:FLGT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Fulgent Genetics (NASDAQ:FLGT) Income Statement, Balance Sheet and Cash Flow Statement
Fulgent Genetics (NASDAQ FLGT) Stock Chart for Thursday, April, 26, 2018
Loading chart…
